



PRESS RELEASE

Lyon (France), 3rd January 2018

Half-year review of the liquidity contract

Pursuant to the liquidity contract established by **AMOEBA** with PORTZAMPARC Trading Company, as of **31st December 2017**, the liquidity account held the following assets:

- **11,706 AMOEBA shares,**
- **EUR 38,070.41**

It is recalled that at the time of **implementation**, the following amount was held in the liquidity account:

- **200,000.00 euros.**



About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating waterborne bacterial risk in water treatment and wound care applications. Our solutions represent alternatives to chemical products widely used in the cooling water treatment and the wound care market. In a global market for chemical biocides estimated to be worth EUR 21 bn(4) AMOEBA is focusing on the industrial cooling tower application estimated at EUR 1.7 bn(5). Similarly, in a global wound care market estimated at EUR 15.2bn(1), AMOEBA is targeting the chronic wound care market in the USA, estimated to be worth EUR 751 million(3). The use of Willaertia magna C2c Maky in health care products will be subject to FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological biocide for water treatment, BIOMEBA, has not yet been granted marketing authorization in the USA, Europe and Canada. AMOEBA is taking the required regulatory steps to be granted marketing authorization in those regions for the use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. More information on www.amoeba-biocide.com.

(1) *marketsandmarkets.com*, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

(2) *M. Diligence*, "Wound Management: An \$18.5 billion+ worldwide market in 2021," *MedMarket Diligence*, 10 June 2013. [Online]. Available: <http://blog.mediligence.com/2013/06/10/wound-management-an-18-5-billion-worldwide-market-in-2021/>. [Accessed 14 February 2017].

(3) *BCC Research*, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017.

(4) : Sources combinées par Amoéba venant des traiteurs d'eau, de Freedomia, d'Eurostat et MarketsandMarkets

(5) : Données Amoéba combinées à partir des sources : DRIRE 2013, Eurostat, ARHIA 2013



Contacts:

Amoéba

Nathalie COMBROUSSE

Marketing Communication Manager

Tel. : +33 (0)4 81 09 18 15

nathalie.combrousse@amoeba-biocide.com

Actifin

Ghislaine GASPARETTO

Financial Communication

Tel. : +33 (0)1 56 88 11 11

ggasparetto@actifin.fr